Arizona State Retirement System raised its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Rating) by 2.4% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 33,974 shares of the biopharmaceutical company’s stock after purchasing an additional 803 shares during the […]
ANTIPODES PARTNERS Ltd purchased a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Rating) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 118 shares of the biopharmaceutical company’s stock, valued at approximately $28,000. A number of other institutional investors and hedge funds […]
Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Rating) announced its quarterly earnings data on Thursday. The biopharmaceutical company reported ($1.40) EPS for the quarter, beating the consensus estimate of ($1.97) by $0.57, Briefing.com reports. The firm had revenue of $319.29 million for the quarter, compared to the consensus estimate of $312.53 million. Alnylam Pharmaceuticals had a negative […]
Parametrica Management Ltd cut its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Rating) by 31.4% during the fourth quarter, HoldingsChannel reports. The fund owned 9,500 shares of the biopharmaceutical company’s stock after selling 4,339 shares during the quarter. Alnylam Pharmaceuticals comprises approximately 4.6% of Parametrica Management Ltd’s holdings, making the stock its 8th biggest […]
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Rating) CEO Yvonne Greenstreet sold 7,615 shares of the stock in a transaction on Thursday, April 27th. The stock was sold at an average price of $194.59, for a total value of $1,481,802.85. Following the transaction, the chief executive officer now directly owns 30,332 shares in the company, valued […]